Chronic lymphocytic leukaemia
Not recruitingStudy on the Risk of Tumor Lysis Syndrome in Adults with Untreated Chronic Lymphocytic Leukemia Using Venetoclax, Obinutuzumab, or Acalabrutinib
Study on the Risk of Tumor Lysis Syndrome in Adults with Untreated Chronic Lymphocytic Leukemia Using Venetoclax, Obinutuzumab, or Acalabrutinib
- Disease:Chronic lymphocytic leukaemia
- Substances:AcalabrutinibObinutuzumab+1
Spain- Participants:18–64 years · 65+ years
- Substances:Acalabrutinib
- Sponsor:AbbVie Deutschland GmbH & Co. KG












